Caffeinated Coffee Consumption and Health Outcomes in the US Population: A Dose–Response Meta-Analysis and Estimation of Disease Cases and Deaths Avoided

• Published in: Advances in nutrition (Bethesda, Md.) Md.), 2021-07, Vol.12 (4), p.1160-1176
• Main Authors: Di Maso, Matteo, Boffetta, Paolo, Negri, Eva, La Vecchia, Carlo, Bravi, Francesca
• Format: Article
• Language: English
• Subjects: attributable fraction; caffeinated coffee consumption; Carcinoma, Hepatocellular; Coffee; Diabetes Mellitus, Type 2; dose–response shape; health outcomes; Humans; Liver Neoplasms - epidemiology; Liver Neoplasms - prevention & control; Outcome Assessment, Health Care; Prospective Studies; Review; Risk Factors; United States - epidemiology; US population
• ISSN: 2161-8313; 2156-5376
• DOI: 10.1093/advances/nmaa177

To explore the role of coffee on health outcomes in the United States, where coffee consumption is common, we conducted a meta-analysis of prospective studies investigating the magnitude (any compared with no consumption) and the dose–response shape (cups per day) of the associations between caffeinated coffee consumption and incidence/mortality of cardiovascular disease (CVD), as well as incidence of type 2 diabetes (T2D), hepatocellular carcinoma (HCC), endometrial cancer, melanoma, and nonmelanoma skin cancer. We selected the desirable health outcomes that have been shown to be positively associated with coffee consumption. Studies were identified by searching PubMed/Embase databases up to September 2019. Inclusion criteria included prospective studies that investigated the relation of ≥3 categories of caffeinated coffee consumption and the outcomes of interest. Twenty-six studies (42 distinct cohorts), with 93,706 cases/deaths and 3,713,932 participants, met the inclusion criteria. In any coffee consumers, there was a significant inverse association with the risk of CVD (RR = 0.90; 95% CI: 0.84, 0.96), T2D (RR = 0.90; 95% CI: 0.85, 0.96), endometrial cancer (RR = 0.85; 95% CI: 0.78, 0.92), melanoma (RR = 0.89; 95% CI: 0.80, 0.99), and nonmelanoma skin cancer (RR = 0.92; 95% CI: 0.89, 0.95). Coffee consumption was also inversely associated with HCC (RR = 0.93; 95% CI: 0.80, 1.08), without reaching statistical significance. The dose–response relation was nonlinear uniquely for CVD (P-nonlinearity = 0.01). In particular, the largest risk reduction was observed for 3–4 cups/d (∼120 mL/cup) and no reduction thereafter. For other outcomes, the risk decreased linearly over the whole coffee consumption range. Current patterns of consumption in the United States would account for a fraction of avoided cases/deaths ranging from 6% to 12% according to the outcome considered. This study confirms the beneficial health effects of caffeinated coffee consumption in the US population on the health outcomes considered, and quantifies their possible magnitude.